Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22297407 | 0.94 | CHRM5 (0.45) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL24745065 | 0.94 | ACHE (0.42) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL12717798 | 0.89 | CHRM5 (0.44) | GNAO1GNAI3GNAI1CHRM5ADRA2C | |
| SCHEMBL23173902 | 0.89 | NCF1 (0.54) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL25571706 | 0.89 | NCF1 (0.54) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL3436997 | 0.87 | NCF1 (0.52) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL18873648 | 0.85 | NCF1 (0.46) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL24319476 | 0.85 | NCF1 (0.50) | NCF1GNAO1GNAI3GNAI1CACNA2D1 | |
| SCHEMBL22307041 | 0.83 | GNAO1 (0.47) | NCF1GNAO1GNAI3GNAI1ACHE | |
| SCHEMBL24334496 | 0.83 | NCF1 (0.45) | NCF1GNAO1GNAI3GNAI1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2023081476-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023077441-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | NCF1 3023/4885GNAO1 1248/4885GNAI3 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.